A Phase 2 Study of Erdafitinib in patients with Advanced Solid Tumours and FGFR Gene Alterations

This study seeks to evaluate the efficacy of erdafitinib in terms of overall response rate in participants with advanced solid tumours with FGFR (fibroblast growth factor receptor) mutations and gene fusions.

Erdafitinib is a selective and potent pan FGFR 1-4 inhibitor with demonstrated clinical activity in those with metastatic urothelial cancer and cholangiocarcinoma who have alterations in the FGFR pathway

Participants with FGFR mutations and FGFR gene fusions will receive a dose of erdafitinib oral tablets.

This international trial is open and recruiting at the following locations in the UK:

Bristol Haematology and Oncology Centre
Bristol, BS2 8ED

Freeman Hospital
Newcastle, NE7 7DN

Derriford Hospital
Plymouth, PL6 8QH

The Royal Marsden NHS Trust
Sutton, SM2 5PT

The Clatterbridge Cancer Centre
The Wirral, CH63 4JY

Not yet recruiting:
The Christie NHS Foundation Trust
Manchester, M20 4BX

For more details, and for European and other locations, see:

Sponsors and Collaborators
Janssen Research & Development, LLC

Back to previous page